Eleusis and Silver Spike Acquisition Corp. II Mutually Agree to Terminate Business Combination Agreement
June 09 2022 - 4:05PM
Business Wire
Eleusis, a clinical-stage life science company that aims to
unlock the therapeutic potential of psychedelics, and Silver Spike
Acquisition Corp. II (“Silver Spike II” or “SPKB”) (NASDAQ:
SPKB/SPKBU/SPKBW), a publicly traded special purpose acquisition
company (“SPAC”), today announced that they have mutually agreed to
terminate their previously announced agreement and plan of merger
(the “Business Combination Agreement”), effective immediately, as a
result of current unfavorable market conditions.
Silver Spike II intends to continue in its efforts to identify a
prospective target business for an initial business
combination.
Additional information about the termination of the Business
Combination Agreement will be provided in a Current Report on Form
8-K to be filed by SPKB with the U.S. Securities and Exchange
Commission (the “SEC”) and available at www.sec.gov.
About Eleusis
Founded in 2013, Eleusis is a life science company dedicated to
transforming psychedelics into mainstream medicines, The company’s
comprehensive discovery and development capabilities, together with
the care delivery platform of Andala-managed clinics, are designed
to target a broad spectrum of unmet needs within and beyond
psychiatry.
About Silver Spike Acquisition Corp. II
Silver Spike Acquisition Corp. II, an affiliate of Silver Spike
Capital, is a blank check company focused on the cannabis and
alternative health and wellness industries, formed for the purpose
of effecting a merger, amalgamation, share exchange, share
purchase, reorganization, or similar business combination with one
or more businesses.
Its management team and board of directors are composed of
veteran cannabis and finance industry executives and founders,
including Scott Gordon, founder and CEO of the company, and Dr.
Orrin Devinsky, director of the company, who is the director of the
NYU Langone Comprehensive Epilepsy Center and is a professor of
neurology, neuroscience, psychiatry and neuroscience at the NYU
School of Medicine and who since 2016 has served as Chair of the
Medical Advisory Board at Tilray.
Forward-Looking Statements
This document contains certain “forward-looking statements”
within the meaning of the federal securities laws, including with
respect to the pursuit by Silver Spike Acquisition Corp. II
(“Silver Spike II”) of a business combination transaction. These
forward-looking statements are generally identified by words such
as “anticipate,” “believe,” continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “strive,” “would” or
the negatives of these words or words of similar meaning.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Such forward-looking statements are based upon
the current beliefs and expectations of the management of Silver
Spike II and are inherently subject to significant business,
economic and competitive risks, uncertainties and contingencies.
Forward-looking statements are subject to numerous conditions, many
of which are beyond the control of Silver Spike, including those
set forth in the “Risk Factors” section of Silver Spike II’s
Quarterly Reports on Form 10-Q, Silver Spike’s registration
statement, the preliminary prospectus for Silver Spike’s offering
and other documents filed by Silver Spike II from time to time with
the U.S. Securities and Exchange Commission (the “SEC”). You are
cautioned not to place undue reliance on these forward-looking
statements as a predictor of future results, performance and/or
achievements as projected financial information and other
information are based on estimates and assumptions, whether or not
identified in this document, that are inherently subject to various
significant risks, uncertainties, contingencies and other factors,
many of which are difficult to predict and generally beyond the
control of the parties involved in the proposed transaction. These
filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Silver Spike II assumes no obligation and does not
intend to update or revise these forward-looking statements,
whether as a result of new information, future events, or
otherwise. Silver Spike II gives no assurance that it will achieve
its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220609006021/en/
Media and Investors For
Eleusis: Alex Speiser, Corporate Development Director
Email: alexander.speiser@eleusisltd.com For Silver Spike Acquisition Corp. II:
Investors: Bill Healy, Partner and Head of Capital Formation
Bill@silverspikecap.com 212-905-4933 Media: Alan Oshiki and Will
Braun, Abernathy MacGregor SilverSpikeCapital@abmac.com
212-371-5999
Silver Spike Acquisition... (NASDAQ:SPKB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Silver Spike Acquisition... (NASDAQ:SPKB)
Historical Stock Chart
From Aug 2023 to Aug 2024